Killexams P3OF Exam Braindumps includes latest syllabus of Portfolio- Programme and Project Offices Foundation exam with up-to-date exam contents | Actual Questions - Mahfia.tv
PDF Exam Questions and Answers : P3OF Exam Braindumps contains complete pool of P3OF Questions and answers in PDF format. PDF contains actual Questions with April 2024 updated Portfolio- Programme and Project Offices Foundation Braindumps that will help you get high marks in the actual test. You can open PDF file on any operating system like Windows, MacOS, Linux etc or any device like computer, android phone, ipad, iphone or any other hand held device etc. You can print and make your own book to read anywhere you travel or stay. PDF is suitable for high quality printing and reading offline.
VCE Exam Simulator 3.0.9 : Free P3OF Exam Simulator is full screen windows app that is like the exam screen you experience in actual test center. This sofware provide you test environment where you can answer the questions, take test, review your false answers, monitor your performance in the test. VCE exam simulator uses Actual Exam Questions and Answers to take your test and mark your performance accordingly. When you start getting 100% marks in the exam simulator, it means, you are ready to take real test in test center. Our VCE Exam Simulator is updated regularly. Latest update is for April 2024.
Exin P3OF Exam Braindumps
We offer Exin P3OF Exam Braindumps containing actual P3OF exam questions and answers. These Exam Braindumps are very useful in passing the P3OF exams with high marks. It is money back guarantee by killexams.com
Real Exin P3OF Exam Questions and Answers
These P3OF questions and answers are in PDF files, are taken from the actual P3OF question pool that candidate face in actual test. These real Exin P3OF exam QAs are exact copy of the P3OF questions and answers you face in the exam.
Exin P3OF Practice Tests
P3OF Practice Test uses the same questions and answers that are provided in the actual P3OF exam pool so that candidate can be prepared for real test environment. These P3OF practice tests are very helpful in practicing the P3OF exam.
Exin P3OF Exam Braindumps update
P3OF Exam Braindumps are updated on regular basis to reflect the latest changes in the P3OF exam. Whenever any change is made in actual P3OF test, we provide the changes in our P3OF Exam Braindumps.
Complete Exin P3OF Exam Collection
Here you can find complete Exin exam collection where Exam Braindumps are updated on regular basis to reflect the latest changes in the P3OF exam. All the sets of P3OF Exam Braindumps are completely verified and up to date.
Portfolio- Programme and Project Offices Foundation Exam Braindumps
Killexams.com P3OF Exam Braindumps contain complete question pool, updated in April 2024 including VCE exam simulator that will help you get high marks in the exam. All these P3OF exam questions are verified by killexams certified professionals and backed by 100% money back guarantee.
P3OF Portfolio, Programme and Project Offices Foundation testing | [HOSTED-SITE]
P3OF testing - Portfolio, Programme and Project Offices Foundation Updated: 2024
Looking for P3OF exam dumps that works in real exam?
P3OF Portfolio, Programme and Project Offices Foundation
Multiple choice examination questions
50 questions per paper with one mark available per question
40 minutes duration
30 marks required to pass (out of 50 available) – 60%
Closed book.
The P3O® certification scheme has been developed to offer two levels of certification, Foundation and Practitioner. AXELOS has accredited PeopleCert as our Examination Institute (EI) and PeopleCert then accredits a network of Accredited Training Organizations (ATOs), including their trainers and course material. The ATOs and accredited trainers offer P3O training courses and examinations.
The purpose of the Foundation certification is to confirm that you have sufficient knowledge and understanding of the P3O guidance to interact effectively with, or act as an informed member of, an office within a P3O model. The Foundation certification is a pre-requisite for the Practitioner certification.
The Portfolio, Programme and Project Offices (P3O®) guidance provides advice, supported
by discussion and examples, on how to develop a governance structure that helps optimize
an organizations investment in change alongside its Business as Usual work.
P3O qualifications are currently offered are two levels: Foundation and Practitioner.
The primary purpose of the syllabus is to provide a basis for accreditation of people involved
with P3O. It documents the learning outcomes related to the use of P3O and describes the
requirements a candidate is expected to fulfil in order to demonstrate that these learning
outcomes have been achieved at each qualification level.
The target audience for this document is:
exam Board
exam Panel
APMG Assessment Team
Accredited Training Organizations
This syllabus informs the design of the exams and provides accredited training organizations
with a breakdown of what the exams will assess. Details on the exam structure and content
are documented in the P3O Foundation and Practitioner Designs.
The purpose of the Foundation qualification is to confirm that a candidate has sufficient
knowledge and understanding of the P3O guidance to interact effectively with, or act as an
informed member of, an office within a P3
The candidate should understand the key principles and terminology within the P3O
guidance. Specifically the candidate should understand the:
High-level P3O model and its component offices
Differences between Portfolio, Programme and Project Management
Key functions and services of a P3O
Reasons for establishing a P3O model
Differences between types of P3O model and the factors that influence selection of the most appropriate model
Processes to implement or re-energize a P3O
Tools and techniques used by a P3O
Purpose and major responsibilities of the defined roles
Level Topic
Key PPM definitions:
1. PPM
2. Portfolio, programme and project
3. Portfolio, programme and project management
4. Business as Usual
What a P3O is:
1. Definition of P3O
2. The potential elements of a P3O model and their definitions Understand key concepts relating to the Overview, Principles of a P3O model and its elements including the Introduction to P3O.
Specifically to identify:
Key concepts of a P3O:
1. The objectives of and differences between portfolios, programmes and projects
2. The objectives of and differences between portfolio, programme and project management and how they help to deliver change
The organizational context of P3O:
1. The relationship between Business as Usual, change and PPM
2. How the elements of a P3O model align to portfolio, programme and project lifecycles
How a P3O provides a decision-enabling/deliverysupport model and how each P3O model element helps to deliver change
What a P3O is:
1. The relationships between the elements in a P3O model and the organization
2. The objectives and key functions of each P3O model element
Portfolio, Programme and Project Offices Foundation Exin Portfolio, testing
If you are confused that how to pass P3OF P3OF Exam? With the help of the killexams.com P3OF P3OF VCE exam Simulator you will learn how to polish your abilities. The majority of the certified professionals start identifying when they discover that they have to seem in IT certification. Our brain dumps are complete and to the point. The P3OF P3OF PDF documents make your imaginative and prescient large and assist you lots in instruction of the certification exam.
Exin
P3OF
Portfolio, Programme and Project Offices Foundation
https://killexams.com/pass4sure/exam-detail/P3OF
Which of the following are key responsibilities of the Portfolio Analyst role?
1. Balance the portfolio in terms of strategic change against business as usual
2. Make recommendations on an appropriate programmeproject balance
3. Provide a fast-track prog
4. Highlight problems relating to project interdependences
A. 1, 2, 3
B. 1, 2, 4
C. 1, 3, 4
D. 2, 3, 4 Answer: B Question: 145
What is the MOST appropriate use of project planning software for an organization at
P3M3 maturity level 1?
A. Collaborative
B. Individual
C. Integrated
D. Networking Answer: B Question: 146
Which of the following describe a decentralized P3O model?
1. Uses hub offices to support local need
2. Has a single office providing support to the entire organization
3. Has a central office typically providing portfolio support
4. Uses standards set by a central COE with local variations
A. 1,2,3
B. 1,2,4
C. 1,3,4
D. 2,3,4 Answer: C
44 Question: 147
Which is an underlying success factor of a P3O model with Hub Portfolio Offices that
enables appropriate localized application of standards?
A. Tailoring core standards to meet local need
B. Planning resource capacity at a local level
C. Reviewing the Blueprint regularly
D. Following a clearly defined business strategy Answer: A Question: 148
What role provides facilitated workshops to promote consistent project management
practice?
A. Project Specialist
B. Project Officer
C. Head of Project Office
D. Secretariatadministrator Answer: A Question: 149
Which is a section of the Blueprint?
A. Business process swimlanes
B. Information portal
C. Vision Statement
D. Processes (including operational costs and performance levels) Answer: D Question: 150
Which of the following describe the governance responsibilities of a P3O model?
1. Provides the governance and control backbone for an organization's change initiatives
2. Provides a single source for all data relating to the organization's change initiatives
45
3. Implements rules for decision-making relating to programmes and projects
4. Makes decisions on behalf of the main board
A. 1, 2, 3
B. 1, 2, 4
C. 1, 3, 4
D. 2, 3, 4 Answer: A
46
For More exams visit https://killexams.com/vendors-exam-list
Kill your exam at First Attempt....Guaranteed!
Morningstar analysts use two types of scenario analysis to forecast potential outcomes for portfolios.
Market-Driven Scenarios
Market-driven scenarios calculate the probable impact of past market events. Zero in and explore how changes to a single index or security can affect your investment or portfolio. What would happen to your portfolio if the S&P 500 fell by 10% this year? By 15%?
By adjusting the length of the scenario’s duration, the percentile of the distribution, and the type of market shock, you can pressure-test your portfolios in a range of possible scenarios.
Market-driven scenarios can help you answer questions like:
How would a fund’s projected performance look? How does that compare to the index?
How likely is any projected outcome? Would this shock trigger volatility and uncertainty?
What does this reveal about the possible worst-case outcomes for the fund?
You can compare data points that assess the impact of market shocks, positive or negative, on:
Factor exposure.
Portfolio return.
Value at Risk—the potential of loss with a given probability.
Conditional Value at Risk—mean loss of a portfolio below the user-specified percentile.
Stock-market scenarios prepare you to ask more informed questions and deeply analyze underlying holdings. See how a portfolio compares to a benchmark index and target sector allocation, or evaluate individual risk factor exposures at the portfolio level.
Macrofinancial Scenarios
Calculates the impact of user-specified macroeconomic and financial system shocks. If the 2007-09 subprime mortgage crisis happened today, how would your portfolio perform? Would it beat a relevant benchmark? If not, how would adjusting individual securities close the gap?
Macrofinancial scenarios help you understand the drivers of market risk in historical scenarios and apply your findings to forward-looking decisions. They can answer questions like:
How would my portfolio perform in a severe or long-lasting bear market?
How am I capturing the upside of regional economic tailwinds or sector booms?
Evaluate investment portfolios under past macrofinancial scenarios like:
Global macroeconomic events, like the novel coronavirus outbreak.
U.S.-specific events, like the mid-2011 showdown over the debt ceiling.
Emerging markets events, like the 2006 selloff.
European markets events, like the 2010 Greek debt crisis.
While the past doesn’t predict the future, you can ground your expectations for fund or portfolio performance under macro headwinds. Evaluate data points like:
Projected cumulative returns.
Alpha.
Max drawdown.
Return.
Standard deviation.
Tracking error.
In Morningstar Direct Lens, you can also create custom scenarios and see how macroeconomic variables affect a portfolio’s risk and return.
Custom scenarios allow you to turn up and down the intensity of different factors for deeper levels of analysis. Specify multiple shocks at different points in time and calculate the expected risk and return of the portfolio.
Sat, 30 Dec 2023 23:48:00 -0600entext/htmlhttps://www.morningstar.com/views/blog/portfolio-construction/portfolio-stress-testing8 Best Forex Brokers in the FX Industry to Consider in 2024No result found, try new keyword!Online forex brokers typically enable traders to execute forex transactions using their supported electronic trading platforms. Alongside their proprietary trading software, many online forex brokers ...Thu, 04 Jan 2024 11:00:00 -0600https://www.miamiherald.com/software-business/article283820768.htmlUse REITs To Add Portfolio Diversification
Most American investors gauge their portfolio performance against a couple of familiar benchmarks: The S&P 500 index or the Dow Jones Industrial index.
That’s understandable, because those indexes are ubiquitous in the media. U.S. investors can be forgiven for believing that the S&P 500 and the Dow - which track large-cap domestic stocks - are the only indexes worth tracking.
It’s true that the S&P 500 represents about 80% of the investable U.S. market, so it’s worth owning, for that reason.
But it’s far from the only game in town.
In the second quarter, real estate investment trusts, as an asset class, outperformed global equity markets.
The S&P Global ex US REIT Index, which tracks 396 publicly traded equity REITs listed in developed and emerging markets, showed a net decline of 4.29% in the third quarter, net of dividends. That outpaced the S&P 500, whose total return was negative 6.44%.
But the Dow Jones US Select REIT Index boasted a total return in positive territory, ending the quarter up 3.09%.
Why is this important for investors to know?
Publicly traded REITs are not a substitute for other equity assets. However, because REITs are not always highly correlated to stocks, they offer portfolio diversification. In particular, investors may want to consider equity, rather than mortgage REITs.
Equity REITs own commercial properties directly. Their portfolios typically include shopping malls, medical centers, public storage units and office buildings.
Mortgage REITs don’t own the hard assets, but finance their ownership. For that reason, mortgage REITs should be considered debt instruments.
When discussing REITs to add diversification, I’m referring to equity REITs. Most investors understand that some kind of exposure to real estate is a good idea, but who wants that call in the middle of the night that the pipes burst?
Instead, REITs are that a truly passive investment. By law, a REIT must pay at least 90% of income to shareholders. The owners of the hard assets receive rental income, which they may increase over time. In addition, because REIT valuations are tied to real estate, whose prices move more slowly than stock prices, they tend to be less volatile.
Now, does all of this mean REITs are somehow guaranteed to top the S&P during any given time frame? Of course not. Despite the third-quarter performance of the overall asset class, the largest REIT exchange-traded fund, the Vanguard REIT Index Fund ETF (ticker: VNQ), is down 5.63% year-to-date. The S&P 500, meanwhile, is showing a decline of about 1.46 percent.
Lack of correlation is exactly the point of diversification, and the reason to add REITs to a globally allocated stock-and-bond portfolio.
It should be noted: At times, REITs have high correlations to either stocks or bonds. However, as it's impossible to predict when REITs may show similar returns to either asset class, it's important to hold REITs at all times. For example, in a portfolio that's invested invested 50% in stocks and 50% in fixed income, equity REITs may represent about 3% of total holdings.
Investors run into trouble when trying to predict how any given asset class will perform. That's as true of REITs as with any other asset.
For example, some investors believe there is forecasting value in a "worst-to-first" scenario. If an asset class is at the bottom of the pile one year, the theory goes, it should bubble up to the top in the following calendar year.
Unfortunately, things don't always work out so neatly. In 2007, as the real-estate market and broader economy were taking a hit, U.S. REITs underperformed 11 other stock and bond asset classes. The following year, when anything that even resembled a stock was demolished, U.S. REITs skidded 39.2%, a slightly worse performance than domestic large-cap stocks.
Another illustration of the inherent difficulty of so-called "tactical" allocation (which is really just making economic bets) as it applies to REITs occurred in 2011. In 2010, U.S. REITs outpaced 11 other stock-and-bond asset classes. That was no small feat, as both equities and fixed income enjoyed good returns that year.
Investors who tried to outsmart markets by selling U.S. REITs were disappointed in 2011, as the asset class was once again a top performer, returning 9.4%.
While the benefits of diversification through publicly-traded entities is apparent, investors should realize that not all REITs are the same. Earlier, I noted the difference between equity REITs and mortgage REITs.
However, there is another important distinction when it comes to REITs: Non-traded REITs are, almost by definition, less transparent than their exchange-listed counterparts. In addition, these investments are usually illiquid. Investors are required to leave their money in place for some specified period of time, usually no less than seven years. In addition, brokers often receive a hefty commission for selling these investments, which is why they are popular with salespeople.
Third-quarter index returns. Source: Dimensional Fund Advisors
Sun, 15 Nov 2015 08:50:00 -0600Kate Stalterentext/htmlhttps://www.forbes.com/sites/katestalter/2015/11/15/use-reits-to-add-portfolio-diversification/Quality testing for antibodies is gaining traction
Monoclonal antibodies for research should be validated in each application usedCredit: Alfred Pasieka/SPL/Getty
Antibodies are invaluable tools in the life sciences. Their high specificity and selectivity for unique protein targets make them indispensable research reagents. Scientists worldwide spend nearly US$2.5 billion a year on antibodies to detect and quantify the expression of proteins in cells and tissues1.
However, lately, the quality of these reagents has come under intense scrutiny. Not all of them seem to be as selective and specific as was assumed, leading to incorrect, inconsistent and irreproducible results2. Alarm bells sounded in 2012 when independent laboratories were unable to replicate the results of 47 out of 53 landmark cancer research papers3.
“The field has been hampered by antibodies that recognize the wrong (or multiple) protein isoforms and antibodies that don’t work well in particular applications,” says Andrew Waters, a postdoctoral researcher at the University of North Carolina, Chapel Hill. Waters’s own dissertation work was significantly delayed because of an antibody that recognized a nonspecific protein of the same molecular weight as his target protein.
Antibody underperformance can significantly drain research time and money. Months, sometimes years, can be spent trying to replicate experiments or proceed with work that is based on incorrect conclusions. To address this growing problem, researchers need to be aware of the issues surrounding these reagents — and antibody manufacturers need to set higher quality standards.
Common issues and how to avoid them
Although antibodies are designed to recognize a target protein, they may not be able to do so in all applications —namely, those that alter the target protein’s structure. Thus, antibodies should be Verified in the application of interest.
Antibody performance can also be hampered by binding to off-target proteins when the target is expressed at low levels or has many isoforms. These potential obstacles can be assessed by using appropriate positive and negative controls prior to carrying out the experiment.
Different batches of antibody can produce dramatically different results. Because antibodies are often referred to simply by brand name, it is important to check the manufacturer’s lot number and characterization data. This information is often omitted in published articles, making it very hard to track down the real antibody that was used — and reproduce the findings.
Lack of training in the use of research antibodies compounds these risks. “Many young scientists fail to appreciate the need to confirm that their antibody works in their set-up,” says Giovanna Roncador, head of the Monoclonal Antibody Unit at Centro Nacional de Investigaciones Oncológicas in Madrid.
With colleagues from the European Monoclonal Antibodies Network (EuroMabNet), Roncador has produced a comprehensive set of guidelines to avoid common pitfalls in research antibody use4. Their recommendations include: defining the target antigen and the experimental techniques that will be used to identify it; conducting a thorough search of the literature to find information on existing antibodies; assessing the available validation data and determining what further validation measures are required; and providing all the necessary protocol and antibody details so others can reproduce the findings.
Other organizations are helping with training: societies such as ISAC (International Society for the Advancement of Cytometry) and ICCS (International Clinical Cytometry Society) are producing webinars and educational materials to help junior scientists select and handle research antibodies.
However, determining an antibody’s sensitivity, specificity and reproducibility in a given application — across experiments and over time — is a complex and costly process that researchers can't do on their own. Experts from industry and academia have come together to develop standard guidelines for antibody validation.
Rigorous antibody validation is achieved by testing that the antibody binds to the right target in the application of interest. This involves using at least one of nine specificity tests in the applications shown above.
Establishing validation standards
The International Working Group for Antibody Validation (IWGAV) is a consortium of leading protein scientists formed in 2015, and supported by the global life sciences company Thermo Fisher Scientific. The IWGAV has proposed five approaches for antibody validation: using genetics; using anorthogonal (non-antibody) strategy; using independent antibodies binding to the same target; correlating antibody labelling with the expression of tagged proteins; and immunoprecipitation followed by mass spectrometry5. At least one of these strategies should be used when validating an antibody for a specific application. Thermo Fisher has used these recommendations as the basis for its own internal systematic approach for verifying the specificity and functionality of antibodies created for its Invitrogen brand (see ‘Two-part approach for antibody verification’).
Deepa Shankar, director for research and development at Thermo Fisher Scientific, explains: “We want to help researchers make an informed choice by producing the most compelling data showing that an antibody works.” Her team is devoted to validating the company’s large antibody portfolio — testing them using Thermo Fisher's two-part approach. “We spend a lot of time ensuring that we test our antibodies in the right environment, in multiple models and in different applications,” she says. “Our aim is to build trust with the scientific community and help advance their research.”
Detailed testing protocols and results, as well as published antibody data, are collated on the company’s website. “Customer feedback is really positive,” says Shankar. “We are seeing a growing number of publications using our antibodies demonstrating that they are working.”
In recognition of these efforts, Thermo Fisher won the 2018 CiteAb Award for the best antibody validation initiative. “Rigorous validation procedures are not in place in many laboratories. Lack of awareness, resources and funds means researchers are relying on vendors to provide good antibodies,” explains Paul Wallace, director of the Department of Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center in Buffalo, New York, and a panel member on Thermo Fisher’s Antibody Validation Forum. “I am very impressed by how Thermo Fisher is taking responsibility for the quality of its antibody products — and is open to dialogue with users.”
Bright outlook
The first step in solving any problem is to recognize that it exists. Since the issue of antibody validation was exposed, it has been openly discussed — and many initiatives set up to find the best solutions. “We are making headway, but a lot more still needs to be done to figure out what are the best strategies to address the problem,” says Wallace. Agreeing to the need for antibody validation standards is a significant first step. Given the importance of reproducibility for the advancement of science, it is in the interest of all researchers and suppliers to step up to the challenge of implementing these standards.
Mon, 27 Aug 2018 14:39:00 -0500entext/htmlhttps://www.nature.com/articles/d42473-018-00082-4Roche expands COVID testing portfolio with $1.8bn GenMark deal
Roche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic capabilities and adding rapid COVID tests to its pandemic arsenal.
GenMark’s tests are designed to rapidly detect multiple pathogens from a single patient sample.
Of particular interest at the moment are its Respiratory Pathogen Panels, which identify the most common viral and bacterial organisms associated with upper respiratory infection, including SARS-CoV-2 – which the companies note will complement Roche’s existing portfolio of COVID-19 diagnostics.
But GenMark also has a range of other infectious disease testing capabilities, including detection of bloodstream infections and antibiotic resistance genes, that are of interest to Roche.
Roche Diagnostics CEO Thomas Schinecker said rapid testing in these areas can help provide “faster targeted therapeutic intervention, resulting in improved patient outcomes and reduced hospital stays, and will contribute to Roche’s commitment to helping control infectious diseases and antibiotic resistance”.
Infectious diseases are a leading cause of death globally, and earlier detection of the cause of an infection has been shown to Excellerate patient outcomes and Excellerate key hospital initiatives such as antibiotic stewardship and length of stay.
Meanwhile, GenMark said that the deal will help expand the reach of its products.
“Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world,” commented Scott Mendel, CEO of GenMark Diagnostics. “We are thrilled to become a part of Roche and are confident that this is the right path forward for GenMark and our customers.”
The merger agreement has been unanimously approved by the boards of directors of GenMark and Roche and the acquisition is expected to close in Q2 2021.
Roche is buying GenMark at a price of $24.05 per share in an all-cash transaction. This corresponds to a total transaction value of approximately $1.8 billion on a fully diluted basis.
This price represents a premium of approximately 43% to GenMark’s unaffected closing share price on 10 February 2021, the last trading day before a media report was published speculating about a potential sale process.
Listen to our exact podcast interview with Roche Diagnostics' Dr Ashton Harper here.
Sun, 14 Mar 2021 12:00:00 -0500entext/htmlhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-dealGenetic testing articles from across Nature Portfolio
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Tue, 19 Dec 2023 09:59:00 -0600entext/htmlhttps://www.nature.com/subjects/genetic-testingTricentis expands its mobile testing portfolio with release of Tricentis Device Cloud
Tricentis has introduced Tricentis Device Cloud (TDC) as a new addition to its mobile testing product lineup.
With this addition, organizations can effectively manage, create, execute, and analyze applications on physical mobile devices from various manufacturers such as Apple, Samsung, and Google throughout the development process.
This eliminates the need to maintain costly and unreliable in-house devices. By identifying crucial mobile failures and performance problems, development teams can swiftly address defects and expedite high-quality releases through their CI/CD pipelines.
“We believe all the pain points for mobile testing are not yet solved, and we’re on a mission to address them in a simplified, seamless way,” said Mav Turner, CTO of DevOps at Tricentis. “Tricentis Device Cloud is another key piece of technology supporting our commitment to helping organizations innovate on high-quality mobile apps faster so they can deliver seamless digital experiences, increase customer engagement and satisfaction, and generate more revenue.”
The Mobile AI engine utilizes machine learning to analyze vast volumes of data and detect potential issues at an early stage. It monitors over 130 Key Performance Indicators (KPIs), including audio-visual quality, network connectivity, and image changes, which enables application development teams to identify bottlenecks and address problems promptly.
Key features include single-tenant and multi-tenant global deployment, real device and cross-device testing, UI testing, and performance optimization focusing on front-end, single-user performance testing.
Build your portfolio and react to the markets in real time. Compete against your friends or coworkers to earn your spot at the top of the leaderboards.
Login required to play. Virtual Stock Exchange game is intended for individuals ages 16 and older.
* We're talking virtual cash, not real money. This is strictly a simulation.
With VSE you can
Trade stocks in real-time using your virtual portfolio
Talk strategies with others in your game
Create a customized public games for others to play
Choose a custom list of symbols to trade in your game
Fully Responsive
A consistent and elegant experience across any device and screen size.
Advanced Trading
You can enable advanced options like limit and stop loss orders, as well as partial shares.
Create Watchlists
You can build and monitor custom watchlists alongside your holdings.
Custom Gameplay
You set the starting budget and can allow margin trading, short selling and more.
If you are a teacher, professor or instructor of students over 16 years of age looking to play a free stock market game with your class, you can use these documents to get started.
Yes. You must complete registration and create an account to join and play. It takes less than a minute and is, of course, free. Remember, you also gain access to key features on MarketWatch when you register for the game.
Use the email address and password you created when you registered. If you forget your password, there's a link to help you in the login area.
Sure. Just click Profile from the navigation of any page. This gives you access to your account information and games.
We encourage you to either join a game or create one.
No. This is strictly a simulation.
Use the expansive collection of news & research tools across MarketWatch to help you decide. For example, quote pages like this one allows you to chart a stock's progress, examine in-depth financials, read its latest announcements and much more to help you make informed decisions.
You bet. Please check out these following MarketWatch pages full of valuable information for investors:
Investing - News and analysis to help investors make crucial decisions
Tools - The research and tools page provides a countless amount of invaluable investor tools such as stock screeners, market screeners, IPO calendar, Earnings Calendar, and a mutual Fund finder tool
Market Data - View the latest Index updates, U.S. Stock Movers, ETF Movers, and New 52 week high/lows for the NYSE and NASDAQ
No exact Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
No results foundNo results foundNo results found
This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.
Tue, 10 Oct 2023 11:32:00 -0500entext/htmlhttps://www.marketwatch.com/gamesTime To Rethink The Classic 60/40 Portfolio?
A stalwart of retirement investing has been the 60/40 portfolio, consisting of 60% equities and 40% bonds.
The idea behind the 60/40 portfolio is to provide growth through stocks, but dampen volatility on the fixed income side. Historically, that means using short-term bonds with high credit quality, which historically have mitigated the risk of stocks.
Bonds also traditionally served a role to generate income.
The 60/40 rule lost some credence during the dot-com boom in the late 1990s, as stocks raced higher, and investors quite reasonably asked themselves: What was the point of owning bonds, which would drag down performance?
These days, financial advisors generally put clients’ assets in portfolios allocated to meet risk tolerance, time horizons and financial goals. That means using ETFs or mutual funds to diversify and smooth returns.
After a client takes a risk assessment quiz, his or or her portfolio is invested in a typical equity-to-fixed income model, such as 60/40, 50/50 or 40/60. For younger investors, or those able to take more risk because of their situation, sometimes a 70/30 portfolio will work, or even a portfolio with a higher allocation into equities.
Retiring During Market Downturn
But the 60/40 portfolio has been the mainstay of portfolios constructed by advisors.
What happens when markets tank? Theoretically, and as advisors are fond of telling clients, stocks and bonds typically don’t move in tandem. If stocks are down, the bond portion of the portfolio is there to pick up the slack.
Again, theoretically, that means if a client is retiring during a broad equity market downturn, he or she can make withdrawals from bond holdings. That way, clients aren’t selling stocks at lows, locking in portfolio losses, which can take months or years to recover.
Simultaneously, this strategy involves selling the fixed income assets, which are trading at higher prices.
This has been a tried-and-true strategy for generating retirement income.
But does it still work? Should advisors and retail investors consider retiring this strategy?
In a January webinar, BlackRock BLK noted that the traditional 60/40 portfolio as implemented by advisors will fail to generate the expected returns of that past. More alarmingly, BlackRock believes the 60/40 portfolio will increase investment risk.
Redesigning The 60/40
Low yields and low expected returns mean bonds will not contribute to overall performance, nor play their traditional role mitigating the risk of stocks. BlackRock warned that the 60/40 portfolio is likely to generate a lower return that it has over the past decade.
If that’s the case, advisors will have to take steps to redesign the 60/40 portfolio so clients meet their retirement income goals.
In a December 2020 white paper, T. Rowe Price TROW examined the role of bonds in the 60/40 portfolio.
Researchers arrived at some bold conclusions. For starters, given an expectation nominal yields to remain low going forward, investors should look to their equity allocations to generate higher returns. Alternately, investors could also increase equity exposure beyond 60%.
“It appears that the status quo of a 60/40 allocation is expected to lead to a lower nominal return outcome than has been achieved historically,” said T. Rowe Price.
Second, the firm recognized that government bonds continue to have a part in a diversified portfolio, “even with low or negative yields.”
Flat Bond Returns?
However, investors may have to adjust their expectations about the magnitude of these diversification benefits. This is related to researchers’ belief that bond returns will be essentially flat during periods of market stress.
Third, the paper examined redesigning and rethinking the construction of the 60/40 portfolio. It explored adding to the equity positions; investing in longer-dated bonds, which are less affected by current central bank policies; using cash to invest in diversification strategies, such as currencies, corporate bonds or gold.
Ultimately, the brokerage came to the conclusion that low bond yields will continue to affect performance of the traditional 60/40 portfolio. Iinvestors should avail themselves of methods to shore up these portfolios without substantially increasing risk.
Sat, 13 Mar 2021 05:36:00 -0600Kate Stalterentext/htmlhttps://www.forbes.com/sites/katestalter/2021/03/13/time-to-rethink-the-classic-6040-portfolio/Abbott's Diversified Portfolio Is Its Secret Sauce
Image courtesy of Matt Smith / Alamy Stock Photo
COVID-19 test sales may have been the star of the show for Abbott in the first quarter, but the company's diversified product portfolio certainly played a supporting role – just as it has donethroughout the pandemic.
The Abbott Park, IL-based company reported $5.3 billion in diagnostics sales, which included $3.3 billion in COVID-related testing sales (mostly from rapid tests such as the BinaxNOW test). The company's medical device business brought in $3.6 billion in sales for the quarter.
"While investors may shrug off COVID test sales, this business generates strong cash flow, with even greater impact to the bottom line as volumes have increased, and serves as a tool to help offset gross margin headwinds from macroeconomic pressures," Marie Thibault, a medtech analyst at BTIG and a former managing editor atMD+DI, noted in a report.
Even if you take out the COVID testing, Abbott's sales grew nearly 8% compared to the same quarter last year. Overall, Abbott reported total sales across its businesses of $11.9 billion.
FreeStyle Libre sales see double-digit growth
The company's $3.6 billion in medical device sales was driven by double-digit growth in diabetes care, structural heart, heart failure, and electrophysiology devices. In diabetes care, sales ofFreeStyle Libregrew more than 25% on an organic basis during the first quarter, and CEO Robert Ford said the user base has now reached about 4 million.
"I'm starting to really see now what we had always envisioned this market to start to be, which is a market that is shifting from what traditionally was more of a type 1, more of a pumper – insulin pump kind of connectivity play, which is an important segment – but really start to move and expand beyond that," Ford said. "And we're starting to see signs of that. And I think Libre is a big driver. The value proposition of Libre is a big driver, whether it's physicians and payers, quite frankly, starting to see the value of the sensing technology across a much broader set of patients."
He also noted that more than 40% of the FreeStyle Libre user base is already people with type 2 non-intensive diabetes.
Abbott product highlights
Abbott highlighted several product wins from the first quarter, including:
Sign up for the QMED & MD+DI Daily newsletter.
Exam Simulator 3.0.9 uses the actual Exin P3OF questions and answers that make up Exam Braindumps. P3OF Exam Simulator is full screen windows application that provide you the experience of same test environment as you experience in test center.
We are a group of Certified Professionals, working hard to provide up to date and 100% valid test questions and answers.
Who We Are
We help people to pass their complicated and difficult Exin P3OF exams with short cut Exin P3OF Exam Braindumps that we collect from professional team of Killexams.com
What We Do
We provide actual Exin P3OF questions and answers in Exam Braindumps that we obtain from killexams.com. These Exam Braindumps contains up to date Exin P3OF questions and answers that help to pass exam at first attempt. Killexams.com develop Exam Simulator for realistic exam experience. Exam simulator helps to memorize and practice questions and answers. We take premium exams from Killexams.com
Why Choose Us
Exam Braindumps that we provide is updated on regular basis. All the Questions and Answers are verified and corrected by certified professionals. Online test help is provided 24x7 by our certified professionals. Our source of exam questions is killexams.com which is best certification exam Braindumps provider in the market.
97,860
Happy clients
245
Vendors
6,300
Exams Provided
7,110
Testimonials
Premium P3OF Full Version
Our premium P3OF - Portfolio- Programme and Project Offices Foundation contains complete question bank contains actual exam questions. Premium P3OF braindumps are updated on regular basis and verified by certified professionals. There is one time payment during 3 months, no auto renewal and no hidden charges. During 3 months any change in the exam questions and answers will be available in your download section and you will be intimated by email to re-download the exam file after update.
Contact Us
We provide Live Chat and Email Support 24x7. Our certification team is available only on email. Order and Troubleshooting support is available 24x7.
